HPV vaccination of girls offers benefits to men but does not reduce risk of some cancers
the ONA take:
The association between human papillomavirus (HPV) and cervical cancer in women is well established.
Furthermore, vaccinating girls has had a positive impact on the incidence of cervical cancer in many countries in which the practice was adopted.
Men benefit indirectly from vaccinating girls in that their risk of contracting HPV is reduced; however, this does not protect men from cancers associated with the virus.
The HPV vaccine has been found effective in boys, but universal vaccination of boys is practiced in only a few countries (Australia, Austria, two Canadian provinces, and the United States).
Dutch researchers sought to estimate the benefit to men if boys were vaccinated against HPV, as well.
Their findings show that benefits from vaccinating boys would not be as significant as they are in girls. Therefore, the researchers suggest that programs for vaccinating girls should continue but including boys may be warranted.
Men benefit indirectly but not from cancer risk associated with the virus.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|